Copyright Reports & Markets. All rights reserved.

Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Icotinib
      • 1.4.3 Gefitinib
      • 1.4.4 Erlotinib
      • 1.4.5 Afatinib
      • 1.4.6 Osimertinib
      • 1.4.7 Brigatinib
      • 1.4.8 Other
    • 1.5 Market by Application
      • 1.5.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Application (2014-2025)
      • 1.5.2 Squamous Cell Carcinoma of NSCLC
      • 1.5.3 Adenocarcinoma of NSCLC
      • 1.5.4 Large Cell Carcinoma of NSCLC
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size
    • 2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Growth Trends by Regions
      • 2.2.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Regions (2014-2025)
      • 2.2.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by by Players
      • 3.1.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue by by Players (2014-2019)
      • 3.1.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
    • 3.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players Head office and Area Served
    • 3.3 Key Players Targeted Drug EGFR RTK Inhibitors for NSCLC Product/Solution/Service
    • 3.4 Date of Enter into Targeted Drug EGFR RTK Inhibitors for NSCLC Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type (2014-2019)
    • 4.2 Global Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
    • 5.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in United States
    • 5.3 United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
    • 5.4 United States Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

    6 Europe

    • 6.1 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
    • 6.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Europe
    • 6.3 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
    • 6.4 Europe Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

    7 China

    • 7.1 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
    • 7.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in China
    • 7.3 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
    • 7.4 China Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

    8 Japan

    • 8.1 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
    • 8.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Japan
    • 8.3 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
    • 8.4 Japan Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
    • 9.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Southeast Asia
    • 9.3 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
    • 9.4 Southeast Asia Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

    10 India

    • 10.1 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
    • 10.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in India
    • 10.3 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
    • 10.4 India Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size (2014-2019)
    • 11.2 Targeted Drug EGFR RTK Inhibitors for NSCLC Key Players in Central & South America
    • 11.3 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Type
    • 11.4 Central & South America Targeted Drug EGFR RTK Inhibitors for NSCLC Market Size by Application

    12 International Players Profiles

    • 12.1 Beta Pharma
      • 12.1.1 Beta Pharma Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
      • 12.1.4 Beta Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
      • 12.1.5 Beta Pharma Recent Development
    • 12.2 AstraZeneca
      • 12.2.1 AstraZeneca Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
      • 12.2.4 AstraZeneca Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
      • 12.2.5 AstraZeneca Recent Development
    • 12.3 Natco Pharma
      • 12.3.1 Natco Pharma Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
      • 12.3.4 Natco Pharma Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
      • 12.3.5 Natco Pharma Recent Development
    • 12.4 Qilu Pharmaceutical
      • 12.4.1 Qilu Pharmaceutical Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
      • 12.4.4 Qilu Pharmaceutical Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
      • 12.4.5 Qilu Pharmaceutical Recent Development
    • 12.5 Genentech (Roche Group)
      • 12.5.1 Genentech (Roche Group) Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
      • 12.5.4 Genentech (Roche Group) Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
      • 12.5.5 Genentech (Roche Group) Recent Development
    • 12.6 Mylan
      • 12.6.1 Mylan Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
      • 12.6.4 Mylan Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
      • 12.6.5 Mylan Recent Development
    • 12.7 Teva
      • 12.7.1 Teva Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
      • 12.7.4 Teva Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
      • 12.7.5 Teva Recent Development
    • 12.8 OSI Pharmaceuticals
      • 12.8.1 OSI Pharmaceuticals Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
      • 12.8.4 OSI Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
      • 12.8.5 OSI Pharmaceuticals Recent Development
    • 12.9 Glenmark Pharmaceuticals
      • 12.9.1 Glenmark Pharmaceuticals Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
      • 12.9.4 Glenmark Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
      • 12.9.5 Glenmark Pharmaceuticals Recent Development
    • 12.10 Beacon Pharmaceuticals
      • 12.10.1 Beacon Pharmaceuticals Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Targeted Drug EGFR RTK Inhibitors for NSCLC Introduction
      • 12.10.4 Beacon Pharmaceuticals Revenue in Targeted Drug EGFR RTK Inhibitors for NSCLC Business (2014-2019)
      • 12.10.5 Beacon Pharmaceuticals Recent Development
    • 12.11 Boehringer Ingelheim
    • 12.12 Pfizer
    • 12.13 ARIAD Pharmaceuticals (Takeda)
    • 12.14 Genvio Pharma Limited
    • 12.15 Drug International Limted
    • 12.16 Everest Pharmaceuticals
    • 12.17 Incepta Pharmaceuticals Limited
    • 12.18 Cipla Pharma
    • 12.19 Dr Reddy's Laboratories
    • 12.20 Zydus Cadila
    • 12.21 Hetero Drugs
    • 12.22 Intas Pharmaceuticals
    • 12.23 Alkem Laboratories
    • 12.24 RPG Life Sciences
    • 12.25 Fresenius Kabi India

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Targeted Drug EGFR RTK Inhibitors for NSCLC market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Targeted Drug EGFR RTK Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drug EGFR RTK Inhibitors for NSCLC development in United States, Europe and China.

      The key players covered in this study
      Beta Pharma
      AstraZeneca
      Natco Pharma
      Qilu Pharmaceutical
      Genentech (Roche Group)
      Mylan
      Teva
      OSI Pharmaceuticals
      Glenmark Pharmaceuticals
      Beacon Pharmaceuticals
      Boehringer Ingelheim
      Pfizer
      ARIAD Pharmaceuticals (Takeda)
      Genvio Pharma Limited
      Drug International Limted
      Everest Pharmaceuticals
      Incepta Pharmaceuticals Limited
      Cipla Pharma
      Dr Reddy's Laboratories
      Zydus Cadila
      Hetero Drugs
      Intas Pharmaceuticals
      Alkem Laboratories
      RPG Life Sciences
      Fresenius Kabi India

      Market segment by Type, the product can be split into
      Icotinib
      Gefitinib
      Erlotinib
      Afatinib
      Osimertinib
      Brigatinib
      Other

      Market segment by Application, split into
      Squamous Cell Carcinoma of NSCLC
      Adenocarcinoma of NSCLC
      Large Cell Carcinoma of NSCLC

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Targeted Drug EGFR RTK Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players.
      To present the Targeted Drug EGFR RTK Inhibitors for NSCLC development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Targeted Drug EGFR RTK Inhibitors for NSCLC are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now